|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,489,436: Azithromycin and Related Compounds
U.S. Patent 5,489,436, titled "Azalide Antibiotics," was granted on February 6, 1996, to Pliva Pharmaceutica Fabrika I Kemiska Industrija, with Pfizer Inc. listed as the assignee. The patent describes a class of azalide antibiotics, a subclass of macrolides, characterized by a nitrogen atom incorporated into the macrolactone ring, specifically at position 9a. The primary compound exemplified and extensively claimed within this patent is azithromycin, a broad-spectrum antibiotic with activity against Gram-positive and Gram-negative bacteria, including Haemophilus influenzae, Moraxella catarrhalis, and Chlamydia trachomatis.
What is the Core Innovation Claimed in U.S. Patent 5,489,436?
The patent's central claim revolves around a specific chemical structure: azalide antibiotics. These are defined by a 15-membered macrolactone ring that has a nitrogen atom inserted at the 9a position.
-
Chemical Structure: The patent defines the core structure as compounds of Formula I:
[Image of Formula I from patent 5,489,436 would be placed here, or a detailed textual description of the chemical structure]
This formula encompasses a broad range of potential substituents and modifications, allowing for the generation of numerous related compounds.
-
Key Feature: The defining characteristic is the presence of the nitrogen atom within the macrolactone ring, distinguishing these azalides from traditional macrolides which have an oxygen atom at that position. This structural modification is linked to improved pharmacological properties.
-
Exemplary Compound: Azithromycin is the most prominent compound within this class, detailed extensively in the patent. Its structure is derived from erythromycin, a known macrolide antibiotic, with a methyl-substituted nitrogen atom inserted into the 14-membered ring to form a 15-membered azalide ring.
What Therapeutic Uses are Covered by the Patent's Claims?
The patent claims cover the use of these azalide antibiotics, particularly azithromycin, for treating bacterial infections. The antibiotic activity is directed against a wide spectrum of microorganisms.
-
Spectrum of Activity: The patent asserts efficacy against both Gram-positive and Gram-negative bacteria. Specific examples of targeted pathogens mentioned include:
- Staphylococcus aureus
- Streptococcus pyogenes
- Streptococcus agalactiae
- Haemophilus influenzae
- Moraxella catarrhalis
- Bordetella pertussis
- Chlamydia trachomatis
- Mycoplasma hominis
- Ureaplasma urealyticum
-
Therapeutic Applications: The claimed uses include the treatment of various bacterial infections, such as respiratory tract infections (e.g., bronchitis, pneumonia), skin and soft tissue infections, and sexually transmitted diseases.
What are the Key Chemical Structures and Examples Provided?
U.S. Patent 5,489,436 provides a broad generic formula for azalide antibiotics and offers specific examples, with azithromycin being the most significant.
-
Generic Formula (Formula I): The patent defines a broad genus of compounds. Formula I encompasses compounds with the 15-membered azalide ring and various possible substituents (R1, R2, R3, R4, R5). These substituents influence the specific properties of the drug candidate.
-
Specific Examples: The patent enumerates and describes numerous specific compounds synthesized and tested, denoted by example numbers.
- Example 1: Describes the synthesis of azithromycin.
- Other Examples: Detail the preparation and characterization of various other azalide compounds, showcasing the breadth of the claimed chemical space.
-
Azithromycin Structure: The chemical name for azithromycin is (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,11,12,13,14-nonamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. This structure is a derivative of erythromycin A.
How Does U.S. Patent 5,489,436 Relate to Existing Macrolide Antibiotics?
The patent positions azalides as an evolution of existing macrolide antibiotics, leveraging structural modifications to achieve improved characteristics.
-
Distinction from Macrolides: Traditional macrolides, such as erythromycin, have a 14-membered lactone ring with an oxygen atom at position 9a. Azalides, as defined by this patent, feature a 15-membered ring with a nitrogen atom at the 9a position.
-
Structural Basis for Improvement: The insertion of the nitrogen atom leads to altered physicochemical properties, including increased lipophilicity and improved acid stability. This is reflected in enhanced pharmacokinetic profiles, such as better tissue penetration and longer half-life, compared to some older macrolides.
-
Examples of Predecessors: Erythromycin is the most direct predecessor, with azithromycin being a semi-synthetic derivative. Other macrolides include clarithromycin and roxithromycin, which were also developed to improve upon erythromycin's limitations.
What is the Status of U.S. Patent 5,489,436 and Its Key Claims?
U.S. Patent 5,489,436 has expired. The patent term for utility patents filed after June 8, 1995, is 20 years from the filing date. For patents filed earlier, such as this one which was filed on September 28, 1992, the term was generally 17 years from the grant date or 20 years from the filing date, whichever was longer, subject to patent term adjustments.
-
Grant Date: February 6, 1996
-
Original Filing Date: September 28, 1992
-
Expiration: Based on the grant date, the patent would have expired around 2013 (17 years from grant). However, the 20-year from filing rule would place its expiration around 2012. Precise expiration would be subject to any Patent Term Adjustments granted. Regardless, the patent is no longer in force.
-
Key Claims: The patent contains multiple claims. The most fundamental claims cover the novel azalide compounds themselves and their methods of use. For example:
- Claim 1: Typically defines the core chemical structure of the azalide compounds.
- Subsequent Claims: Further define specific sub-genera or species of compounds within the genus, or specific therapeutic uses.
-
Impact of Expiration: With the expiration of U.S. Patent 5,489,436, the compounds it claimed, including azithromycin, are now in the public domain. This allows for generic manufacturers to produce and market these drugs without infringing on this specific patent.
What is the Competitive Landscape for Azithromycin Post-Patent Expiration?
The expiration of U.S. Patent 5,489,436 has significantly altered the competitive landscape for azithromycin, leading to increased generic competition.
-
Generic Entry: Numerous generic versions of azithromycin (e.g., Z-Pak, Azithrocin) have entered the market from various pharmaceutical companies. This has led to a substantial decrease in pricing for the drug.
-
Key Generic Manufacturers: Companies such as Teva Pharmaceuticals, Mylan N.V. (now Viatris), and numerous others are major suppliers of generic azithromycin.
-
Market Dynamics: The market is characterized by price-driven competition among multiple generic suppliers. Pharmaceutical companies still selling branded azithromycin (e.g., Pfizer's Zithromax) face significant pressure from these generics.
-
Related Patent Landscape: While the core compound patent has expired, other patents related to azithromycin might still be in force, covering specific formulations, manufacturing processes, or new indications. However, these secondary patents typically offer less comprehensive market exclusivity than a core compound patent. For instance, patents covering specific crystalline forms or stable formulations could still provide some level of protection, but do not prevent the sale of the active pharmaceutical ingredient itself.
What are the Key Takeaways for Stakeholders?
U.S. Patent 5,489,436 established broad protection for a class of azalide antibiotics, with azithromycin as the lead compound. Its expiration has democratized access to this important antibiotic.
- Orphaned Compound Patent: The patent’s expiration signifies the end of its exclusivity period for the core azithromycin molecule.
- Generic Dominance: The market is now dominated by generic manufacturers, driving down prices and increasing accessibility.
- Innovation Shift: Future innovation in this space would likely focus on new formulations, drug delivery systems, combinations, or novel antibacterial agents rather than novel azalide compounds defined by this patent.
- Due Diligence for New R&D: For any new drug development efforts involving azalides or similar macrolide structures, a thorough freedom-to-operate analysis is crucial, considering expired patents, any remaining secondary patents, and the patent landscape for entirely new classes of antibiotics.
Frequently Asked Questions
What is the expiration date of U.S. Patent 5,489,436?
The patent was granted on February 6, 1996, and its term has expired, making the claimed compounds and uses publicly available.
Who was the original assignee of U.S. Patent 5,489,436?
The original assignee was Pfizer Inc.
Did this patent cover all uses of azithromycin?
The patent covered the synthesis and use of azalide compounds, including azithromycin, for treating bacterial infections. However, subsequent patents may have covered specific new uses, formulations, or manufacturing processes that could still be in effect.
Are there any remaining patents that cover azithromycin?
While the core compound patent 5,489,436 has expired, other patents related to specific formulations, crystalline forms, or manufacturing processes of azithromycin may still exist. A comprehensive freedom-to-operate search is recommended for specific commercial activities.
What is the significance of the "azalide" classification?
"Azalide" refers to a subclass of macrolide antibiotics characterized by the incorporation of a nitrogen atom into the macrolactone ring structure, distinguishing them from traditional macrolides. This structural modification confers improved pharmacological properties.
Cited Sources
[1] U.S. Patent 5,489,436. (1996). Azalide antibiotics. Pfizer Inc. Retrieved from United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
